BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1174708)

  • 1. Correction of poor platelet transfusion responses with leukocyte-poor HL-A-matched platelet concentrates.
    Herzig RH; Herzig GP; Bull MI; Decter JA; Lohrmann HP; Stout FG; Yankee RA; Graw RG
    Blood; 1975 Nov; 46(5):743-50. PubMed ID: 1174708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of in vitro assays in selection of compatible platelet donors.
    Tosato G; Appelbaum FR; Trapani RJ; Dowling R; Deisseroth AB
    Transfusion; 1980; 20(1):47-54. PubMed ID: 7355471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of cross-matching for transfusion of platelet concentrates to alloimmunized recipients.
    Filip DJ; Duquesnoy RJ; Aster RH
    Am J Hematol; 1976; 1(4):471-9. PubMed ID: 1008059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between donor-recipient lymphocytotoxicity and the transfusion response using HLA-matched platelet concentrates.
    Herzig RH; Terasaki PI; Trapani RJ; Herzig GP; Graw RG
    Transfusion; 1977; 17(6):657-61. PubMed ID: 595123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Substitution ofpolysensitized patients with platelets from HL-A typed single donors].
    Gmür J; Baumberger U; von Felten A
    Schweiz Med Wochenschr; 1976 Oct; 106(40):1358-9. PubMed ID: 1006253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HL-A matching in thrombocyte and leukocyte transfusions.
    Matej H; Olearczyk J; Partyka T; Kotlarek-Haus S; Stawarz M; Dzierzkowa-Borodej W
    Arch Immunol Ther Exp (Warsz); 1975; 23(2):181-7. PubMed ID: 807177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Aster RH
    Blood; 1977 Sep; 50(3):407-12. PubMed ID: 884318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-leukocyte and anti-platelet immunization and transfusions during aplastic anemias].
    Dausset J; Benbunan M
    Nouv Rev Fr Hematol (1978); 1976 Jun; 16(1):132-43. PubMed ID: 781619
    [No Abstract]   [Full Text] [Related]  

  • 9. Single donor, HL-A matched platelet transfusions for thrombocytopenic patients undergoing surgery.
    Kahan BD; Green D; Ruder A; Ranney DF; Hartz WH; Mittal KK
    Surgery; 1975 Feb; 77(2):241-8. PubMed ID: 124097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH
    Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.
    Claas FH; Smeenk RJ; Schmidt R; van Steenbrugge GJ; Eernisse JG
    Exp Hematol; 1981 Jan; 9(1):84-9. PubMed ID: 7238645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
    Eernisse JG; Brand A
    Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates.
    O'Connell BA; Lee EJ; Rothko K; Hussein MA; Schiffer CA
    Blood; 1992 Jan; 79(2):527-31. PubMed ID: 1730095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations.
    Daly PA; Schiffer CA; Aisner J; Wiernik PH
    JAMA; 1980 Feb; 243(5):435-8. PubMed ID: 7351763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets].
    Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T
    Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients.
    Hogge DE; Dutcher JP; Aisner J; Schiffer CA
    Blood; 1984 Jul; 64(1):253-6. PubMed ID: 6733276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thrombocyte replacement with HL-A typed non-related single donors].
    Cornu P; Groff P; Weber W; Nissen C; Burri HP; Speck B
    Schweiz Med Wochenschr; 1976 Jun; 106(26):889-93. PubMed ID: 792998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.